Paulex Bio Registers Phase 1/2a Trial of PAL-119
The first-in-human study plans to enroll healthy volunteers and adults with Type 1 or Type 2 diabetes.
Related stories
Global Stocks Rise as Oil Pullback and Solid Data Lift Sentiment
Global stocks were headed higher after oil prices fell sharply, reversing some of the gloom from Friday’s US tech rout. The Nasdaq was up 1.2% and the S&P 500 rose 1% at the open.
M impact | EQUITY | Nov 02, 2026, 03:46 PM UTC
Cencosud Closes Four Easy Stores in Chile
Cencosud closed four stores in its Easy chain: two in regional areas and two in Santiago.
L impact | EQUITY | Nov 02, 2026, 03:42 PM UTC
Greece Agrees to Acquire Up to Six Embraer KC-390 Jets
Greece agreed to acquire up to six KC-390 Millennium jets from Embraer.
M impact | EQUITY | Nov 02, 2026, 03:41 PM UTC
Cipher Digital Shares Fall After Third-Quarter Revenue Miss
Cipher Digital shares fell Monday morning after the company reported third-quarter revenue below estimates. Bitcoin mining remained the majority of revenue.
M impact | EQUITY | Nov 02, 2026, 03:41 PM UTC
Enerjisa Enerji reports Q3 revenue
Revenue was lower than in the same period last year.
M impact | EQUITY | Nov 02, 2026, 03:40 PM UTC
Enerjisa Enerji Reports Q3 Revenue of 75.8 Billion Lira
Q3 revenue was 75.8 billion lira, versus 78.8 billion lira a year earlier.
M impact | EQUITY | Nov 02, 2026, 03:40 PM UTC